Latham & Watkins LLP represented Arcutis Biotherapeutics in the transaction. Arcutis Biotherapeutics, Inc. announced the pricing of its underwritten public offering of 4,000,000 shares of its…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
